Alex Herrera

69PUBLICATIONS
316CO-AUTHORS
Molecular targetsHaematological tumoursGene expression (incl. microarray and other genome-wide approaches)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (69)

|Oct 22, 2026
Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas.

|Oct 02, 2026
Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma.

|Sep 09, 2026
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.

|Jul 29, 2026
Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).

|Jun 09, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

|Mar 27, 2026
Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Ayo Samuel Falade, Robert Redd, Sanjal H Desai

Pageof 12

Frequent Collaborators

12 joint publications

Mehdi Hamadani

10 joint publications

Lihua Elizabeth Budde

9 joint publications

Geoffrey Shouse

9 joint publications

Mazyar Shadman